Fernwood Investment Management LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,122 shares of the biopharmaceutical company’s stock after selling 478 shares during the quarter. Gilead Sciences comprises about 1.5% of Fernwood Investment Management LLC’s holdings, making the stock its 10th biggest holding. Fernwood Investment Management LLC’s holdings in Gilead Sciences were worth $2,868,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Athena Capital Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $27,000. Capital Financial Planning LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $27,000. Creative Financial Designs Inc. ADV raised its stake in Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares in the last quarter. Claybrook Capital LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $32,000. Finally, We Are One Seven LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $37,000. Institutional investors own 78.68% of the company’s stock.
GILD stock opened at $67.17 on Friday. The company has a market cap of $84.81 billion, a price-to-earnings ratio of 10.92, a price-to-earnings-growth ratio of 0.81 and a beta of 1.14. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.75%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s payout ratio is 40.98%.
In related news, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $62.61, for a total value of $169,047.00. Following the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at $3,603,831.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the transaction, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,602 shares of company stock worth $1,863,445. 0.20% of the stock is owned by insiders.
A number of equities research analysts recently weighed in on the stock. Citigroup raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and set a $66.80 target price on the stock in a research note on Wednesday. Credit Suisse Group assumed coverage on shares of Gilead Sciences in a research note on Monday. They issued a “neutral” rating and a $70.00 target price on the stock. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, May 17th. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, May 17th. Finally, JPMorgan Chase & Co. reissued a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research note on Tuesday, May 7th. Nine equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $80.57.
WARNING: This story was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/24/fernwood-investment-management-llc-has-2-87-million-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: What is the CBOE Russell 2000® Volatility Index?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.